Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of the Use of KRYSTEXXA® (Pegloticase) in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy

NCT01466166 is registered in ClinicalTrials.gov with Horizon Pharma Rheumatology LLC as lead sponsor.

NCT NCT01466166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of the Use of KRYSTEXXA® (Pegloticase) in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy
Lead sponsor
Horizon Pharma Rheumatology LLC
Phase
Observational
Overall status
Completed
Start date
November 15, 2011
Completion date
June 30, 2017
Enrollment
188 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

refractory chronic gout